+

TN2009000119A1 - Combination drug - Google Patents

Combination drug

Info

Publication number
TN2009000119A1
TN2009000119A1 TNP2009000119A TN2009000119A TN2009000119A1 TN 2009000119 A1 TN2009000119 A1 TN 2009000119A1 TN P2009000119 A TNP2009000119 A TN P2009000119A TN 2009000119 A TN2009000119 A TN 2009000119A TN 2009000119 A1 TN2009000119 A1 TN 2009000119A1
Authority
TN
Tunisia
Prior art keywords
combination drug
agent
combination
provides
present
Prior art date
Application number
TNP2009000119A
Other languages
English (en)
Inventor
Yoshikazu Ohta
Toshiya Tamura
Shinji Takagi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of TN2009000119A1 publication Critical patent/TN2009000119A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TNP2009000119A 2006-10-06 2009-04-03 Combination drug TN2009000119A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006275841 2006-10-06
JP2007057902 2007-03-07
PCT/JP2007/070026 WO2008044782A2 (fr) 2006-10-06 2007-10-05 Médicament combiné

Publications (1)

Publication Number Publication Date
TN2009000119A1 true TN2009000119A1 (en) 2010-10-18

Family

ID=39283276

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000119A TN2009000119A1 (en) 2006-10-06 2009-04-03 Combination drug

Country Status (23)

Country Link
US (1) US20100008912A1 (fr)
EP (2) EP2063895A2 (fr)
JP (1) JP2010505745A (fr)
KR (1) KR20090094804A (fr)
CN (1) CN101553222A (fr)
AR (1) AR063152A1 (fr)
AU (1) AU2007307489A1 (fr)
BR (1) BRPI0717477A2 (fr)
CA (1) CA2665692A1 (fr)
CL (1) CL2007002878A1 (fr)
CO (1) CO6180429A2 (fr)
CR (1) CR10759A (fr)
EA (1) EA200970353A1 (fr)
EC (1) ECSP099311A (fr)
GE (1) GEP20115218B (fr)
IL (1) IL197883A0 (fr)
MA (1) MA30815B1 (fr)
MX (1) MX2009003660A (fr)
NO (1) NO20091628L (fr)
PE (1) PE20080977A1 (fr)
TN (1) TN2009000119A1 (fr)
TW (1) TW200823218A (fr)
WO (1) WO2008044782A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP8409A (en) * 2004-06-02 2011-12-20 Fused heterocyclic compound
KR20100038377A (ko) 2007-06-19 2010-04-14 다케다 야쿠힌 고교 가부시키가이샤 암의 예방／치료제
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
WO2011040212A1 (fr) 2009-10-01 2011-04-07 Takeda Pharmaceutical Company Limited Agent thérapeutique pour une tumeur cérébrale
KR101592258B1 (ko) * 2014-06-20 2016-02-05 보령제약 주식회사 제제 및 이의 제조방법
US20180045598A1 (en) * 2016-08-09 2018-02-15 Baker Hughes Incorporated Subsea transition system
EP4121130A4 (fr) * 2020-03-17 2024-03-27 MicroVention, Inc. Agents d'embolisation liquides

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
JPS6019790A (ja) * 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
WO1989006692A1 (fr) * 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
AR041135A1 (es) * 2002-09-04 2005-05-04 Schering Corp Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas
JP4366683B2 (ja) 2003-07-28 2009-11-18 武原 力 熱サイホン
MEP8409A (en) * 2004-06-02 2011-12-20 Fused heterocyclic compound
RU2361589C2 (ru) 2004-06-04 2009-07-20 Смитклайн Бичам (Корк) Лимитед Способ лечения рака
ES2368930T3 (es) * 2004-09-06 2011-11-23 Bayer Pharma Aktiengesellschaft Pirazolopirimidinas como inhibidores de proteína cinasa b (akt).
JP2006275841A (ja) 2005-03-30 2006-10-12 Taiheiyo Cement Corp セメント中のジエチレングリコール量の定量方法
JP2007057902A (ja) 2005-08-25 2007-03-08 Seiko Epson Corp 画像形成装置

Also Published As

Publication number Publication date
MX2009003660A (es) 2009-04-22
GEP20115218B (en) 2011-05-25
CL2007002878A1 (es) 2008-08-01
WO2008044782A3 (fr) 2008-12-11
AU2007307489A1 (en) 2008-04-17
AR063152A1 (es) 2008-12-30
EP2063895A2 (fr) 2009-06-03
KR20090094804A (ko) 2009-09-08
CN101553222A (zh) 2009-10-07
WO2008044782A2 (fr) 2008-04-17
CA2665692A1 (fr) 2008-04-17
BRPI0717477A2 (pt) 2015-06-16
CR10759A (es) 2009-05-27
PE20080977A1 (es) 2008-09-05
TW200823218A (en) 2008-06-01
IL197883A0 (en) 2009-12-24
CO6180429A2 (es) 2010-07-19
EA200970353A1 (ru) 2009-10-30
MA30815B1 (fr) 2009-10-01
NO20091628L (no) 2009-06-26
ECSP099311A (es) 2009-06-30
EP2359825A2 (fr) 2011-08-24
JP2010505745A (ja) 2010-02-25
US20100008912A1 (en) 2010-01-14

Similar Documents

Publication Publication Date Title
TN2009000119A1 (en) Combination drug
WO2007008752A3 (fr) Compositions pharmaceutiques a liberation prolongee pour medicaments tres solubles dans l'eau
WO2007101224A3 (fr) Inhibiteurs de la reponse aux proteines non depliees et procedes d'utilisation
CY1107906T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει παραγωγα οιστετρολης για χρηση στην θεραπεια κατα του καρκινου
ECSP077238A (es) Composiciones para entrega de drogas altamente solubles en agua
WO2006133707A3 (fr) Polytherapie contre le cancer et kit de composants associe
WO2007048027A3 (fr) Combinaison de composes organiques
WO2008023362A3 (fr) Traitement du cancer
PL1845957T3 (pl) Sposób uzyskiwania ekstraktu leku zawierającego hydroksystylben
TW200600091A (en) Sulfonylethyl phosphorodiamidates
HK1114769A1 (en) Antitumor combinations containing a vegf inhibitor and 5fu or one of its derivative
PL369148A1 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
MXPA03001227A (es) Composiciones neuroprotectoras de 2-piridinamina y metodos relacionados.
WO2007128588A3 (fr) Glutadone
MX2009001433A (es) Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica.
SI1869185T1 (sl) Konjugat ki obsega protein P za zdravljenje raka
MXPA05008572A (es) Uso de dipiridamol en combinacion con acido acetilsalicilico y un antagonista de angiotensina ii para la prevencion de accidente cerebrovascular.
GEP20104911B (en) Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues
GB2443377A (en) Anti-malarial composition comprising artesunate and lumefantrine
TW200942544A (en) Combination drug
PL1713438T3 (pl) Mydło lecznicze
GB0313386D0 (en) Treatment of disease
WO2005084671A3 (fr) Combinaison de voriconazole et d'un inhibiteur de cyp2c19 antifongique
DOP2009000066A (es) Farmaco combinado
WO2007012967A3 (fr) Combinaison de voriconazole et de fluconazole
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载